Lianyungang's Enterprises Ranked Top 50 Global Pharmaceutical List in 2023

From: Lianyungang Daily Updated: 2023-06-13 10:37

A few days ago, PharmExec released the ranking of the top 50 global pharmaceutical companies in 2023, and four Chinese pharmaceutical companies including Jiangsu Hengrui Pharmaceuticals Co., Ltd. were on the list. Among them, Hengrui Pharmaceuticals Co., Ltd. ranked 43rd with a total revenue of 21.28 billion yuan in 2022.

It is reported that PharmExec is a well-known professional magazine in the international pharmaceutical industry, providing industry information and strategic decision-making references for top CEOs or managers in the international pharmaceutical industry. This year marks the 23rd time that the magazine has launched the TOP 50 list of global pharmaceutical companies, which is mainly ranked based on the sales revenue of preion drugs by major pharmaceutical companies. Its main data is supported by the well-known pharmaceutical consulting company Evaluate.

The new medicine industry of our city was budding in the 1970s, started in the 1980s, emerged in the 1990s, and entered the fast lane of development after 2000. In August 1969, the Pharmaceutical Factory of the First Division of Jiangsu Production and Construction Corps was set up and renamed as Lianyungang Dongfeng Pharmaceutical Factory in 1973. It was the predecessor of Chiatai Tianqing Pharmaceutical Group; in 1970, Lianyungang Pharmaceutical Factory, the predecessor of Jiangsu Hengrui Pharmaceuticals Co., Ltd., was established; in 1975, the predecessor of Kanion Pharmaceutical, Lianyungang Traditional Chinese Medicine Factory, was established; in July 1995, Lianyungang Hansoh Pharmaceutical Group Co., Ltd. was established. The deputy director of the Municipal Science and Technology Bureau introduced, “These four inconspicuous enterprises at that time have now become the innovation leaders of China's pharmaceutical industry. Among them, Hengrui, Hansoh and Chiatai Tianqing have repeatedly been in the top four of China's pharmaceutical innovation rankings, while Kanion Pharmaceutical firmly occupies the forefront of China's traditional Chinese medicine innovation rankings.”

In the continuous pursuit of integrity and innovation, by the mid-1990s, pharmaceutical enterprises in our city began to rise to the top. The Polyporus Polysaccharide of Dongfeng Pharmaceutical Factory, Ifosfamide of Lianyungang Pharmaceutical Factory and Cinnamomum Twig Poria of Lianyungang Traditional Chinese Medicine Factory hit the market in succession, and the pharmaceutical enterprises in our city began to step on the stage of Chinese pharmaceutical innovation. At present, Hengrui and Hansoh’s anti-tumor drugs, Kanion's traditional Chinese patent medicine, Chiatai Tianqing's anti hepatitis drugs and etc. have laid the foundation for the overall chain of our city's pharmaceutical industry. Zhao Yongsheng, a third level researcher at the Municipal Bureau of Industry and Information Technology, introduced that in 2018, the Municipal Party Committee and Government proposed the idea of building a "Chinese Medicine Port" and set up the goal of "being characterized by Lianyungang identity, national first-class and world renowned". Nowadays, pharmaceutical enterprises in our city firmly occupy the competitive initiative in fields such as anti-tumor, anti-infection, gynecology, anesthesia, surgical medication, liver disease, and many drugs have been included in the national guidelines for the treatment of related diseases, benefiting lots of patients.

A good industrial foundation has led to the emergence of innovative achievements in our city. After years of development, more than 20 pharmaceutical enterprises in our city have been approved for the listing of Class 1 new drugs. We have won 9 National Science and Technology Progress Awards and 5 Chinese Patent Gold Awards in total, and have undertaken over 100 national level major new drug projects in the past three years. Nearly 50 drugs have passed overseas quality certification. Jiangsu Hengrui Pharmaceuticals Co., Ltd. was ranked 13th in the global pharmaceutical innovation index, the only Chinese pharmaceutical enterprise on the list. Up till now, 8 national level biopharmaceutical industry bases and other scientific and technological achievements transformation bases have been approved, and there are over 60 pharmaceutical research and development institutions; 18 national key talent engineering experts are gathered in the field of medicine. Pharmaceutical enterprises have over 10000 high-end innovative talents.